Howe & Rusling’s Black Diamond Therapeutics BDTX Stock Holding History

Howe & Rusling’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50	Closed	–	–	1059
2022 Q2	$0	Buy	+50	New	+$116	﹤0.01%	1057

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Howe & Rusling's BDTX Position: Q3 2022 in Review

Howe & Rusling sold out of Black Diamond Therapeutics (BDTX) in Q3 2022, closing a stake of 50 shares.

Howe & Rusling first reported a position in BDTX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 69 funds tracked by Wall St. Rank hold BDTX as of Q3 2022.

Howe & Rusling reported no remaining Black Diamond Therapeutics position as of Q3 2022 after selling out during the quarter.
Howe & Rusling sold 50 Black Diamond Therapeutics shares in Q3 2022.
Howe & Rusling first reported a position in Black Diamond Therapeutics in Q2 2022 and held it in 1 quarter.
Howe & Rusling's Black Diamond Therapeutics position peaked at $0 in Q2 2022.
69 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.